CRISPR therapeutics have crossed the most critical threshold in biotech: first human approvals. The market is transitioning from promise to commercial reality at extraordinary speed.
December 2023 was the inflection point. The FDA approved Casgevy — developed by Vertex Pharmaceuticals and CRISPR Therapeutics — for sickle cell disease, making it the first CRISPR-based medicine cleared for human use in the United States. The EMA followed weeks later.
This moment is to gene editing what Herceptin's 1998 approval was to targeted oncology: the proof-of-concept that unlocks institutional capital, accelerates pipeline investment, and triggers a new wave of company formation. The companies building in this window — and the infrastructure they build on — will define the category for decades.
The domain that names this category should belong to one of them.
Beyond the first approval, the CRISPR clinical pipeline has never been richer. Programs are advancing in hemoglobinopathies, Duchenne muscular dystrophy, transthyretin amyloidosis, various cancers, Leber congenital amaurosis, and more. Base editing — a next-generation CRISPR approach developed by David Liu's lab at the Broad — is entering Phase 2 trials with a cleaner safety profile than classical Cas9 editing.
In vivo delivery — delivering CRISPR editing machinery directly to tissues in the body without ex vivo cell manipulation — is the frontier attracting the most aggressive investment. Success here would expand the addressable disease universe by an order of magnitude.
The gene editing sector attracted over $8B in venture and growth equity in 2024 alone, with public company market capitalizations adding up to over $40B even after significant drawdowns. Major pharmaceutical companies have committed billions through partnerships, acquisitions, and internal programs.
Vertex paid $4.9B to acquire ViaCyte. Pfizer invested heavily in its own RNA and gene editing pipeline. Eli Lilly, Novartis, and AstraZeneca have all established significant CRISPR-related partnerships. The sector has reached the stage where Big Pharma is no longer watching from the sidelines — they are acquiring, partnering, and building.
Brand positioning in biotech is established early and is expensive to change. The companies that will lead this space in 2035 are largely being founded, funded, and named today. The domain CrisprPharmaceuticals.com is available at the precise moment when the category is being defined — before the consolidation phase that makes repositioning prohibitively costly.
This is the window. It will not remain open indefinitely.
| Segment | 2024 Market | 2030 Projection | CAGR | Key Drivers |
|---|---|---|---|---|
| CRISPR Therapeutics | $3.2B | $18B | ~34% | First approvals, expanding pipeline |
| Base & Prime Editing | $0.8B | $6.5B | ~41% | Superior safety profile, Phase 2 advances |
| Gene Therapy (Viral Vector) | $8B | $24B | ~20% | Rare disease approvals, AAV innovation |
| CAR-T / TCR-T Cell Therapy | $6B | $22B | ~24% | Allogeneic platforms, solid tumor progress |
| In Vivo Gene Editing Delivery | $1.5B | $12B | ~41% | LNP innovation, liver/CNS targeting |
| Genome Sequencing & Diagnostics | $25B | $62B | ~16% | WGS cost collapse, pharmacogenomics |
Both of those facts are temporary. Only one of them is in your control.
Acquire the Domain